Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 30, 2026

SpaceX’s IPO could open the floodgates — and secondaries are booming in the meantime

View original at finance.yahoo.com
SpaceX’s IPO could open the floodgates — and secondaries are booming in the meantime SpaceX's Starship rocket 38 launches during the 11th test flight on October 13, 2025 as seen from South Padre Island in Texas…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Elon Musk famously said he wouldn't take SpaceX public until rockets were flying to Mars regularly

    80% confidence

  • SpaceX IPO will likely be a sliver deal, only 5% of their company that's technically available

    80% confidence

  • SpaceX will get a premium multiple well above what typical market rates would be, given the Elon halo effect

    80% confidence

  • Private companies are staying private much longer now, with many companies that would be top 30 in the S&P 500 historically going public years earlier

    80% confidence

  • If anyone can build data centers in space cooled by space and run by solar panels directly from the sun, Elon's probably the guy

    80% confidence

  • The news that SpaceX may be considering various transactions with xAI and Tesla has caused a temporary pause in the market for SpaceX shares

    80% confidence

  • Companies should open up private secondary capability as a great way to develop price discovery well in advance of the IPO

    80% confidence

  • OpenAI and Anthropic are now over a trillion dollars of combined market cap, though three or four years ago they were valued much lower

    80% confidence

  • SpaceX could create a reset in the IPO market if it were to go public this year

    80% confidence

  • Last year was Rainmaker's biggest year, trading over $1 billion worth of secondaries

    80% confidence

  • SpaceX is already pricing well above where the last tender round was and getting closer to that trillion and a half that they had discussed as a potential IPO price

    80% confidence

  • Jeff Bezos is going to launch a communication network to compete with Starlink

    80% confidence

  • More market cap is now housed in the private markets

    80% confidence

  • Lining up banks is a pretty big signal that SpaceX is serious about IPO, not just playing games

    80% confidence

  • SpaceX has a business that is largely profitable and has dominance in their two key businesses

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
SpaceX’s IPO could open the floodgates — and secondaries are booming in the meantime — Source | Via News | Finance Via News